补中益气丸联合坦索罗辛治疗良性前列腺增生的临床研究

目的 探讨补中益气丸联合盐酸坦索罗辛缓释胶囊治疗良性前列腺增生的临床疗效。方法 选取2017年6月-2018年7月中国中医科学院广安门医院南区治疗的良性前列腺增生患者124例作为研究对象，随机将所有患者分为对照组和治疗组，每组各62例。对照组患者口服盐酸坦索罗辛缓释胶囊，0.2 mg/次，1次/d。治疗组在对照组治疗的基础上口服补中益气丸，4 g/次，2次/d。两组均连续治疗3个月。观察两组患者的临床疗效，同时比较两组治疗前后的临床症状相关指标和血清学指标。结果 治疗后，治疗组总有效率为95.16%，显著高于对照组的85.48%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者前列腺体积、残余尿量（RU）和国际前列腺症状评分（IPSS）均显著降低，最大尿流率（MFR）显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组临床症状显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者游离前列腺特异抗原（fPSA）、总前列腺特异抗原（tPSA）、胰岛素样生长因子-1（IGF-1）和血清脂蛋白磷脂酶A2（Lp-PLA2）水平均明显下降，fPSA/tPSA水平显著上升，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组血清学指标水平均显著优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 补中益气丸联合盐酸坦索罗辛缓释胶囊治疗良性前列腺增生具有较好的临床疗效，可改善患者的临床症状和血清学指标，具有一定的临床推广应用价值。

Clinical study on Buzhong Yiqi Pills combined with tamsulosin in treatment of benign prostatic hyperplasia

Objective To investigate the clinical efficacy of Buzhong Yiqi Pills combined with Tamsulosin Hydrochloride Sustained Release Capsules in treatment of benign prostatic hyperplasia. Methods Patients (124 cases) with benign prostatic hyperplasia in South Campus of Guang''anmen Hospital, China Academy of Chinese Medical Sciences from June 2017 to July 2018 were randomly divided into control and treatment groups, and each group had 62 cases. Patients in the control group were po administered with Tamsulosin Hydrochloride Sustained Release Capsules, 0.2 mg/time, once daily. Patients in the treatment group were po administered with Buzhong Yiqi Pills on the basis of control group, 4 g/time, twice daily. Patients in two groups were treated for 3 month. After treatment, the clinical efficacies were evaluated, and the indicators related to clinical symptoms and serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 95.16%, which was significantly higher than 85.48% in the control group, and there were differences between two groups (P < 0.05). After treatment, the prostate volume, RU, and IPSS in two groups were significantly decreased, but MFR in two groups were significantly increased, and the difference was significant in the same group (P < 0.05). After treatment, the clinical symptoms in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, fPSA, tPSA, IGF-1, and Lp-PLA2 levels in two groups were significantly decreased, but fPSA/tPSA in two groups were significantly increased, and the difference was significant in the same group (P < 0.05). After treatment, the serological indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Buzhong Yiqi Pills combined with Tamsulosin Hydrochloride Sustained Release Capsules has a good clinical effect in treatment of benign prostatic hyperplasia, can improve clinical symptoms and serological indexes, which has a certain clinical application value.